Literature DB >> 7937553

Interspecies scaling of cimetidine-theophylline pharmacokinetic interaction: interspecies scaling in pharmacokinetic interactions.

A R Gascón1, B Calvo, R M Hernández, A Domínguez-Gil, J L Pedraz.   

Abstract

The aim of the present study was the use of an interspecies scaling approach to predict drug interactions during preclinical drug disposition studies. Theophylline and cimetidine were selected because of their documented interaction. The literature was searched for pharmacokinetic data of intravenously administered theophylline alone and in the presence of cimetidine in humans, dogs and rats. Further, we determined the theophylline-cimetidine drug interaction in rabbits. Application of allometric equations to the pharmacokinetic parameters and the conversion of chronological time into pharmacokinetic time allowed us to obtain the complex Dedrick plot for theophylline when administered alone or in combination with cimetidine. A superimposable kinetic profile was obtained for the plasma levels of theophylline in all species studied, both with and without cimetidine. From the terminal phase of the curves it is possible to calculate the elimination half-life: 2.69 apolisychrons for theophylline when it is administered alone and 3.86 apolisychrons when it is administered in combination with cimetidine. This 43% increase in t1/2 is similar to the increase in the elimination half-life of theophylline in humans when it is administered after pretreatment with cimetidine. These results show that an interspecies scaling approach may be useful to predict the effect of interactions in humans from the results obtained in preclinical research with new drugs.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7937553     DOI: 10.1023/a:1018914816137

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  16 in total

Review 1.  Interspecies metabolism and pharmacokinetic scaling of theophylline disposition.

Authors:  F Gaspari; M Bonati
Journal:  Drug Metab Rev       Date:  1990       Impact factor: 4.518

2.  Effects of equimolar doses of cimetidine and ranitidine on theophylline elimination.

Authors:  G I Adebayo
Journal:  Biopharm Drug Dispos       Date:  1989 Jan-Feb       Impact factor: 1.627

3.  Relationship between plasma and whole blood theophylline concentration in neonates.

Authors:  J R Koup; B A Hart
Journal:  J Pediatr       Date:  1979-02       Impact factor: 4.406

4.  Differential effects of cimetidine on theophylline metabolic pathways.

Authors:  J J Grygiel; J O Miners; R Drew; D J Birkett
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

Review 5.  Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm.

Authors:  H Boxenbaum
Journal:  Drug Metab Rev       Date:  1984       Impact factor: 4.518

6.  Statistical moments in pharmacokinetics.

Authors:  K Yamaoka; T Nakagawa; T Uno
Journal:  J Pharmacokinet Biopharm       Date:  1978-12

7.  Interspecies scaling, allometry, physiological time, and the ground plan of pharmacokinetics.

Authors:  H Boxenbaum
Journal:  J Pharmacokinet Biopharm       Date:  1982-04

8.  Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a "parallel tube" model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance.

Authors:  K S Pang; M Rowland
Journal:  J Pharmacokinet Biopharm       Date:  1977-12

9.  Cimetidine-theophylline interaction: effects of age and cimetidine dose.

Authors:  I A Cohen; C E Johnson; R R Berardi; M L Hyneck; S R Achem
Journal:  Ther Drug Monit       Date:  1985       Impact factor: 3.681

10.  Animal model for theophylline--cimetidine drug interaction.

Authors:  W A Ritschel; P S Banerjee; W Cacini; M Hassan; A J Pesce
Journal:  Methods Find Exp Clin Pharmacol       Date:  1985-12
View more
  9 in total

Review 1.  Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations.

Authors:  T Lavé; P Coassolo; B Reigner
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

Review 2.  The pharmacokinetic principles behind scaling from preclinical results to phase I protocols.

Authors:  I Mahmood; J D Balian
Journal:  Clin Pharmacokinet       Date:  1999-01       Impact factor: 6.447

3.  Mixed effect modeling of sumatriptan pharmacokinetics during drug development. I: Interspecies allometric scaling.

Authors:  V F Cosson; E Fuseau; C Efthymiopoulos; A Bye
Journal:  J Pharmacokinet Biopharm       Date:  1997-04

4.  Interspecies scaling for the prediction of drug clearance in children: application of maximum lifespan potential and an empirical correction factor.

Authors:  Iftekhar Mahmood
Journal:  Clin Pharmacokinet       Date:  2010-07       Impact factor: 6.447

5.  Pharmacokinetic and pharmacoimmunodynamic interactions between prednisolone and sirolimus in adrenalectomized rats.

Authors:  G M Ferron; N A Pyszczynski; W J Jusko
Journal:  J Pharmacokinet Biopharm       Date:  1999-02

6.  Fractal volume of drug distribution: it scales proportionally to body mass.

Authors:  V Karalis; L Claret; A Iliadis; P Macheras
Journal:  Pharm Res       Date:  2001-07       Impact factor: 4.200

7.  Correlation of plasma clearance of 54 extensively metabolized drugs between humans and rats: mean allometric coefficient of 0.66.

Authors:  W L Chiou; G Robbie; S M Chung; T C Wu; C Ma
Journal:  Pharm Res       Date:  1998-09       Impact factor: 4.200

Review 8.  Pharmacokinetics and molecular detoxication.

Authors:  J R Cashman; B Y Perotti; C E Berkman; J Lin
Journal:  Environ Health Perspect       Date:  1996-03       Impact factor: 9.031

Review 9.  Scaling basic toxicokinetic parameters from rat to man.

Authors:  K Bachmann; D Pardoe; D White
Journal:  Environ Health Perspect       Date:  1996-04       Impact factor: 9.031

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.